Hande information: to repurchase shares of RMB 50 million to RMB 100 million
Hande information (300170) announced in the evening of November 15 that it planned to repurchase shares of the company for the implementation of equity incentive plan or employee stock ownership plan. The total amount of funds shall not be less than 50 million yuan and not more than 100 million yuan, and the price of shares to be repurchased shall not be more than 15 yuan / share.
Increase holdings and reduce holdings
Baofeng energy: the controlling shareholders plan to increase their holding by RMB 500-1 billion
Baofeng energy (600989) announced on the evening of November 15 that the companys controlling shareholder Baofeng group and its related party Bian Haiyan are firmly optimistic about the companys development, believing that the companys performance is excellent and the industry development space is huge, but at present the companys value is seriously underestimated. Decide to increase the shares of the company. Among them, Baofeng groups proposed increase in shareholding is no less than 300 million yuan and no more than 600 million yuan; Bian HaiYans proposed increase in shareholding is no less than 200 million yuan and no more than 400 million yuan.
Wanze shares: Ganjiang rongchuang plans to invest 15-30 million yuan to increase its holding
Wanze shares (000534) announced in the evening of November 15 that Ganjiang rongchuang, a shareholder, plans to increase its holding of shares of the company in the next six months, with an increase of 15-30 million yuan.
Ren Zixing: the actual controller and its concerted actors plan to reduce their shares by no more than 6%
Ren Zixing (300311) announced on the evening of November 15 that Jing Xiaojun, the controlling shareholder and actual controller of the company, and Jing Xiaodong, the person acting in concert, planned to reduce their holdings of no more than 40.7993 million shares in the next six months, accounting for 6% of the total share capital of the company.
Chengmai Technology: the total number of shares to be reduced by two shareholders is not more than 7.04%
On the evening of November 15, Chengmai Technology (300598) announced that the shareholder, scentshill capital I, plans to reduce its holding of 4.8 million shares, or no more than 6% of the companys total share capital in the next six months; in addition, the shareholder, scentshill capital II, plans to reduce its holding of 831900 shares, or no more than 1.04% of the companys total share capital. In the secondary market, Chengmai technologys share price has risen 183% since October.
Shanghai Airport: passenger throughput in October slightly decreased by 0.77% year on year
Shanghai Airport (600009) announced on the evening of November 15 that in October, the companys passenger throughput was 6.2836 million, down 0.77% year on year; cargo and mail throughput was 328000 tons, up 2.31% year on year.
CSCEC: 2.26 trillion new contracts signed in the first 10 months, up 9.3% year on year
China Construction (601668) announced on the evening of November 15 that the total amount of new contracts signed by the company from January to October was 2269.9 billion yuan, up 9.3% year on year. Among them, the newly signed contract amount of construction business is 1946.6 billion yuan, up 6.7% year on year; the contract sales of real estate business is 314.3 billion yuan, up 28% year on year.
Weitang industry: signed a $3.32 million mold product purchase contract with customers
Weitang industry (300707) announced in the evening of November 15 that the company had recently signed a number of mold product purchase contracts with customers, with a total contract amount of 3.3231 million US dollars.
North Co., Ltd.: signed a sales contract of US $89.19 million for mining vehicles
North stock (600262) announced on the evening of November 15. Recently, the company and Hui Bang Group signed the procurement contract of off highway electric wheel freight dump truck, with a total contract amount of 89.19 million US dollars. This related party transaction is based on the expansion of the companys international market business. The contract is to be performed in 2020, which has no impact on the companys performance in this period and will have a positive impact on the companys performance in 2020, which is conducive to improving the companys sustainable profitability.
Lifan shares: sales volume of new energy vehicles in October fell 64% year on year
Lifan Co., Ltd. (601777) announced on the evening of November 15 that in October, the sales volume of traditional passenger vehicles of the company was 29, down 99.25% year on year; the sales volume of new energy vehicles was 423, down 64.15% year on year; the sales volume of motorcycles was 49569, up 40.48% year on year.
China Eastern Airlines: passenger turnover rose 7.91% year on year in October
China Eastern Airlines (600115) announced in the evening of November 15 that in October, the companys passenger transport capacity investment increased by 9.28% year on year; passenger turnover increased by 7.91% year on year, of which domestic and international passenger turnover increased by 8.19% and 9.85% year on year, and regional passenger turnover decreased by 22.74% year on year; the passenger occupancy rate was 80.82%, down by 1.02% year on year, including domestic, international and regional passenger occupancy rate They decreased by 0.97, 0.54 and 9.87 percentage points year on year respectively.
MCC: the newly signed contract amount in the first 10 months increased by 20.3% year on year
China Metallurgical Corporation (601618) announced on the evening of November 15 that the newly signed contract amount of the company from January to October was 595.06 billion yuan, an increase of 20.3% over the same period of last year, among which the newly signed overseas contract amount was 24.35 billion yuan.
PICC: the original insurance premium income in the first 10 months was 471.63 billion yuan
China Peoples Insurance (601319) announced on the evening of November 15 that the companys original insurance premium income from January to October through its subsidiaries, China Peoples Property Insurance Co., Ltd., China Peoples Health Insurance Co., Ltd. and China Peoples Life Insurance Co., Ltd., was RMB 361.25 billion, RMB 19.994 billion and RMB 90.386 billion respectively.
Air China: passenger turnover rose 2.8% year on year in October
Air China (601111) announced on the evening of November 15 that in October, the combined passenger turnover of the company and its subsidiaries increased year on year and month on month. Investment in passenger transport capacity increased by 2.0% year on year, and passenger turnover increased by 2.8% year on year. Among them, the investment in domestic passenger transport capacity increased by 2.8% year-on-year, and the passenger turnover increased by 2.8% year-on-year; the investment in international passenger transport capacity increased by 1.4% year-on-year, and the passenger turnover increased by 4.6% year-on-year; the average passenger occupancy rate was 81.6%, up 0.6% year-on-year.
China Coal Energy: Sales of commercial coal in October increased by 60% year on year
China coal energy (601898) announced on the evening of November 15 that in October, the sales volume of commercial coal of the company was 23.75 million tons, a year-on-year increase of 60%; the cumulative sales volume from January to October was 186.03 million tons, a year-on-year increase of 36%.
Long term Logistics: to establish a wholly-owned subsidiary in Shanghai Free Trade Zone
Long term logistics (603569) announced on the evening of November 15 that the company plans to establish a wholly-owned subsidiary Shanghai long term International Logistics Co., Ltd. in Shanghai free trade zone with a registered capital of 10 million yuan. The establishment of subsidiaries is conducive to the layout of international logistics business and the optimization of capital turnover.
Huatong Co., Ltd.: planned to build Lishu Huatong agricultural industrial chain project in Lishu County
Huatong Co., Ltd. (002840) announced in the evening of November 15 that the company and Lishu County Government signed the cooperation framework agreement on Lishu Huatong agricultural industrial chain construction project, and the two sides reached cooperation intention on the companys investment and construction of Lishu Huatong agricultural industrial chain construction project in Lishu County. The total investment of the project is planned to be about 1.024 billion yuan.
Jinke culture: sign a strategic cooperation agreement with the hot cloud of China and Guangzhou
Jinke culture (300459) announced in the evening of November 15 that the company signed a strategic cooperation agreement with Zhongguang hot cloud. Among them, Zhongguang hot cloud or its designated subject cooperates with professional investment institutions to launch an investment fund in the field of cultural content creation and dissemination, 5g technology and application, giving priority to investing in Jinke culture and its related projects, becoming an important shareholder of Jinke culture, and making use of the capital market to make greater and stronger with Jinke culture as the platform.
Hengrui pharmaceutical: obtained GMP certificate
Hengrui Pharmaceutical (600276) announced on the evening of November 15 that the company has recently obtained the GMP certificate issued by Jiangsu drug administration. The certified production workshop is 2203 workshop with an annual design capacity of 30 million capsules. The representative product is etoposide soft capsule. Etoposide is a cell cycle specific anti-tumor drug, which is mainly used to treat small cell lung cancer, malignant lymphoma, malignant germ cell tumor, leukemia, neuroblastoma, rhabdomyosarcoma, ovarian cancer, non-small cell lung cancer, gastric cancer and esophageal cancer.
Six countries chemical industry: the court declared the bankruptcy of its holding subsidiary
Liuguo chemical (600470) announced on the evening of November 15 that the peoples Court of Guixi City, Jiangxi Province announced the bankruptcy of its holding subsidiary, Liuguo, Jiangxi. The company has made full provision for impairment of equity investment and accounts receivable of Jiangxi six countries. After the six countries in Jiangxi were taken over by the bankruptcy administrator Jiangxi Huaxing law firm, they are no longer included in the scope of the companys consolidated statements.
CICC Gold: Chairman Song Xin resigns
On the evening of November 15, Zhongjin gold (600489) announced that Song Xin applied to resign as chairman, director, chairman and member of the strategy committee of the board of directors due to the change of work. After resigning, Song Xin will no longer hold any post in the company.
Shangfeng cement (000672) announced in the evening of November 15 that its holding subsidiary, Duan Shangfeng, intends to sign the clinker capacity index transfer agreement with Hami Tianshan Cement Co., Ltd., Aksu Tianshan Duolang Cement Co., Ltd. Kashi branch, Turpan Tianshan Cement Co., Ltd. and other three companies respectively, and plans to replace the capacity index in Duan, Guangxi Build a new dry process cement clinker production line with a daily output of 5000 tons and related supporting projects.
Digital China: sign strategic cooperation framework agreement with China Mobile
Digital China (000034) announced in the evening of November 15 that the company and China Mobile had signed the strategic cooperation framework agreement, and the two sides planned to carry out strategic cooperation in the fields of communication infrastructure, vertical field, cloud computing business, ICT application and smart city.
Crystal optoelectronics: the proposed increase in fundraising is not more than 2.25 billion yuan plus the main business
Crystal Optoelectronics (002273) announced in the evening of November 15 that it is planned to raise no more than 2.25 billion yuan for the technical transformation project of optical components for intelligent terminals, the project of precision thin film optical panel for mobile IOT intelligent terminals and the replenishment of working capital. The raised funds of this non-public offering are all used for the companys main business. While consolidating the companys position in the imaging optics and biometric optical products industry, it extends to precision thin film optical panel products.
Nanshan aluminum: phase II 1 million tons of alumina project funded and expanded by Bai, a subsidiary
Nanshan aluminum (600219) announced on the evening of 15th that Bai, an overseas holding subsidiary, plans to increase its capital to expand the phase II 1 million ton alumina project of Nanshan Industrial Park in Bintan, Indonesia, with a total investment of 3.068 billion yuan. The main source of the capital is raised by the original shareholders of Bai through capital increase and introduction of war investment. Among them, the company has contributed 699 million yuan through Gai, accounting for 22.77% of the total investment of Bai phase II project. The investment of this Bai capital increase and Bai phase II project will not affect the 1 million ton alumina project of Indonesia Bintan Nanshan Industrial Park invested and constructed by the company with the share allotment raised capital in 2017.
Zoomlion Heavy Industry Co., Ltd.: the subsidiary plans to invest in the intelligent agricultural machinery industrialization project
Zoomlion Heavy Machinery Co., Ltd. (000157) announced in the evening of November 15 that its holding subsidiary Zoomlion Heavy Machinery Co., Ltd. plans to invest in the construction of intelligent agricultural machinery industrialization project in Sanshan District, Wuhu City. Zoomlion plans to invest 2.05 billion yuan in 2020-2025, increase investment in research and development, make up for shortcomings, and promote transformation and upgrading of Zoomlions agricultural machinery business.
LMZ: 1.174 billion yuan to sell multiple companies equity and debt stripping paper and real estate related businesses
LMZ (600249) announced on the evening of November 15 that the company plans to sell 84.62% of the shares of paper company, 80% of the shares of Fangkai company, 372 million yuan of creditors rights to paper company, 782 million yuan of creditors rights to paper company and 208800 million yuan of creditors rights to Fangkai company. The total price of this transaction is 1.174 billion yuan. After the completion of the transaction, the company will withdraw part of the capital through the sale of assets, focus on the development of daily chemical, pharmaceutical and other core advantage businesses, and no longer engage in paper and real estate related businesses, which is conducive to the companys ability to enhance sustainable operation.
Huazhong CNC: change of controlling shareholder and actual controller
Huazhong CNC (300161) announced in the evening of November 15 that, based on the current shareholding of the companys shareholders and the composition of the new board of directors, and in accordance with relevant regulations, the controlling shareholder of the company was changed from Wuhan Huazhong Science and technology industry group to Yan Zhi and his concerted action person, Zhuoer intelligent manufacturing (Wuhan) Co., Ltd., and the actual controller was changed from Huazhong University of science and technology to Yan Zhi.
Xinzhu Co., Ltd.: disclosing the commissioning plan of embedded medium and low speed maglev vehicles
Xinzhu Co., Ltd. (002480) announced in the evening of November 15 that the company planned to build a 4.5km embedded medium and low speed maglev comprehensive test line. At present, the work of pile foundation, bearing platform, pier column, beam assembly and girder erection of the remaining lines of the first phase of the test line project is advancing in an orderly manner, and it is expected to be completed in December 2019. After the first phase of the test line is completed as planned, the company will strive to start vehicle commissioning before January 25, 2020, and strive to achieve vehicle speed level of 160km / h in the first half of 2020.
Yiling pharmaceutical: the subsidiary plans to invest 5.034 billion yuan in the construction of modern Chinese medicine industrialization project
In the evening of November 15, Yiling Pharmaceutical (002603) announced that the company plans to Take Hengshui Yiling, a wholly-owned subsidiary, as the main body of the project, invest in the construction of modern Chinese medicine industrialization project of Hengshui Yiling Pharmaceutical Co., Ltd. the products of the project mainly include Chinese medicine formula granules, Chinese medicine tablets and health products. The total investment of the project is planned to be 5.034 billion yuan.
CNNC titanium dioxide: Wang Zelong plans to acquire 27.05% of the equity
CNNP titanium dioxide (002145) announced in the evening of November 15 that Li Jianfeng, the controlling shareholder, intends to transfer 27.05% of the companys equity to Wang Zelong through an agreement. The transaction price is 3.8 yuan / share. After the transfer, the controlling shareholder and actual controller of the company were changed from Li Jianfeng to Wang Zelong.
Lubei chemical: restructuring to acquire Jinhai titanium industry and Xianghai titanium industry resumed on November 18
Lubei chemical (600727) announced on the evening of 15th that the company plans to issue shares and pay cash to Lubei group to acquire 66% of its shares in Jinhai titanium industry, and to issue shares and pay cash to Jinjiang Group to acquire 34% of its shares in Jinhai titanium industry. In addition, the company plans to pay cash to Lubei group to acquire 100% equity of Xianghai titanium. The transaction price of 100% shareholders equity of Jinhai titanium industry is tentatively determined to be 1.38 billion yuan, and that of Xianghai titanium industry is tentatively determined to be 20 million yuan. The shares of the company resumed trading on November 18.
Huabei Pharmaceutical Co., Ltd.: the companys drugs pass the conformity evaluation of generic drugs
Huabei Pharmaceutical (600812) announced on the evening of November 15. Recently, the company received the approval document for supplementary drug application issued by the State Food and Drug Administration for cyclosporine soft capsules (25mg, 50mg). The two specifications of the drug passed the consistency evaluation of quality and efficacy of generic drugs. Cyclosporine soft capsule is an immunosuppressant, which is mainly used to prevent the rejection of allogeneic kidney, liver, heart, bone marrow and other organs or tissues transplantation, and also to prevent and treat GVHD during bone marrow transplantation.
Source: editor in charge of Finance and economics of Netease: Liu Songgou nbj9949